The Dutch Pharmaceutical Company Merus is Being Acquired by its Danish Counterpart Genmab. The Company is Paying Approximately $ 8 Billion (€ 6.8 Billion) for the Utrecht-Based Company. Merus is developing a treatment for cancer in the head and neck area.
Merus’s Shares Have Risen Sharply in Value in recent months. In May, the Company Announced that its drug petosemtamab works Better than the current Standard Treatment for Head and Neck Cancer. It is a drug to reduce the tumor.
The Pharmaceutical Company is Testing Whether the Drug is also effective in the Treatment of Colon Cancer. That Market is potentially much larger and more profitable than the one for head and neck cancer.
Merus was founded in 2003 and also has a location in the United States. Genmab Has Existed Since 1999 and Has Locations All over the world in Addition to its headquarters in Copenhagen. Both Companies Were Unanimously in Favor of the Acquisition.